CSL stock: Buy, hold, or sell in 2025?

Let's see what analysts are saying about this blue chip giant at the start of the year.

| More on:
Woman using a pen on a digital stock market chart in an office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) stock had an underwhelming year in 2024.

During the 12 months, the biotechnology giant's shares traded relatively flat and underperformed the market.

While this is disappointing, has it created a buying opportunity for investors in 2025? Let's find out.

CSL stock: Buy, hold, or sell in 2025?

The good news is that almost all the major brokers currently have the equivalent of buy ratings on CSL's shares at the start of 2025.

The even better news is that the general consensus is that CSL stock could generate big returns over the next 12 months.

Let's look at what a few brokers are saying about the plasma therapies leader.

Over at Morgans, its analysts have an add rating and $330.75 price target on the company's shares. This implies potential upside of almost 15% for investors from current levels.

The broker recently named CSL as one of its Best Calls to Action. It notes that these are "stocks that present compelling buying prospects right now."

Elsewhere, analysts at Macquarie have an outperform rating and $334.00 price target on CSL stock. This suggests that upside of approximately 16% is possible over the next 12 months.

In addition, the broker has previously stated its belief that CSL's shares could hit $500 within three years. This is based on its forecast for strong double-digit earnings growth for the foreseeable future thanks to the CSL Behring plasma business.

What else?

UBS is also bullish on CSL and has a buy rating and $330.00 price target on its shares, and Jarden has an overweight rating and $329.62 price target on them.

But the most bullish broker is arguably Bell Potter, which has a buy rating and $345.00 price target. This implies potential upside of almost 20% for investors in 2025.

Commenting on its buy rating, the broker said:

We expect CSL will achieve guidance of "annual double-digit earnings growth" over the mid-term driven largely by the legacy plasma business, Behring, particularly its immunoglobulin sales. While CSL's Seqirus and Vifor business units do face near-term headwinds (reduced flu market demand and generic iron competition), these two units combined only contribute less than a third of total earnings.

CSL continues to be a high quality, global operator with a multi-year gross margin recovery well underway to drive earnings expansion. The stock is currently trading at a 12m forward PE 27% and 19% below 5- and 10-year averages, respectively.

Overall, this could make the biotech giant one to consider this year.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and Macquarie Group. The Motley Fool Australia has positions in and has recommended Macquarie Group. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements
Broker Notes

What is Morgans saying about TechnologyOne, Wesfarmers, and Xero shares?

Let's see what the broker is saying about these shares.

Read more »

A man looking at his laptop and thinking.
Broker Notes

Are WiseTech shares a buy after its big acquisition?

Let's see what analysts are saying about this tech stock.

Read more »

ASX 200 shares broker downgrade origami paper fortune teller with buy hold sell and dollar sign options
Broker Notes

Are Bendigo Bank shares a buy, hold or sell? Here's Macquarie's latest recommendation

Should I buy the dip on Bendigo Bank shares today?

Read more »

Happy man working on his laptop.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

A female broker in a red jacket whispers in the ear of a man who has a surprised look on his face as she explains which two ASX 200 shares should do well in today's volatile climate
Broker Notes

5 of the best ASX 200 shares to buy in June

Let's see what brokers are recommending to investors for next month.

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Broker Notes

These ASX 200 shares could rise 20% to 100%

Analysts are expecting these shares to deliver big returns over the next 12 months.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

Broker looking at the share price.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »